Cigna vs Laboratory Corporation of America: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cigna Corp (CI)

Q3 202621 Jun – 30 Sep 2026

▲2▼1

Cigna beats Q2, raises guidance, but 2027 headwinds and PBM breakup risk temper outlook

Q2 beat and raised guidance Cigna beat Q2 2026 estimates with $7.78 adjusted EPS and raised full-year guidance to at least $30.45, signaling strong current performance and management confidence.
This is the core positive fundamental result that drove the stock this quarter.
AI initiatives promise cost savings AI initiatives like Pharmacy Forward and expanded care management are expected to cut costs and drive growth, though UBS warns these efficiency gains may be competed away.
AI is a key new growth and efficiency driver highlighted this quarter.
2027 headwinds and downgrade Jefferies downgraded the stock on 2027 headwinds including EviCore/HIX reviews, reduced GLP-1 coverage, and PBM pressure, while Senator Warren's bill threatens to break up vertically integrated PBMs.
These regulatory and business pressures are the main negative forces weighing on the stock.
Employer rebidding and Investor Day targets A UBS survey shows 77% of employers rebidding contracts, though Cigna's Express Scripts PBM may gain share; at Investor Day, Cigna reaffirmed guidance and set long-term targets of 10–14% EPS CAGR and $50B cumulative operating cash flow.
This captures the mixed demand dynamics and long-term strategic outlook presented this quarter.

September 20264 Aug – 30 Sep 2026

▼2▲1

Cigna faces 2027 headwinds, regulatory risk, but AI and new strategy offer support

Jefferies downgrade on 2027 earnings headwinds Jefferies cut Cigna to Hold and lowered its 2027 EPS estimate, citing uncertainty around the EviCore and HIX strategic reviews, reduced GLP-1 coverage, and PBM regulatory pressure. This weighs on the stock because it signals slower growth and limited near-term catalysts.
This is a new analyst action that directly lowers expectations for Cigna's future earnings, a key driver of the stock price.
Warren bill targets PBM vertical integration Senator Warren is pushing a bipartisan bill to break up vertically integrated healthcare companies, explicitly naming Cigna as one of the three major PBMs. If passed, it could force divestitures and reshape Cigna's business model, creating regulatory overhang that pressures the stock.
This is a new regulatory threat that could fundamentally alter Cigna's structure and profitability, directly impacting investor sentiment.
Employer survey shows high rebidding risk but PBM strength UBS survey shows 77% of employers will rebid health contracts for 2027, with Cigna among those with high exposure. However, Cigna's Express Scripts PBM is cited as likely to improve its market position, a positive offset. The net effect is uncertain but highlights competitive pressures.
This new survey data reveals both a risk (high rebidding) and an opportunity (PBM strength) that could affect Cigna's future revenue and market share.
AI expansion and new 'Lead to One' strategy Cigna is expanding AI care coordination and Pharmacy Forward, which could cut costs and improve outcomes. At its Investor Day, it reaffirmed 2026 guidance and set long-term targets of 10-14% EPS CAGR and $50B cumulative operating cash flow, plus a $3B modernization initiative. These support the stock by showing innovation and growth commitment.
These new initiatives and reaffirmed guidance provide a positive counterweight to the negative headwinds, showing management's confidence and potential for efficiency gains.

Latest4 Aug – 30 Sep 2026

▼2▲1

Cigna faces 2027 headwinds, regulatory risk, but AI and new strategy offer support

Jefferies downgrade on 2027 earnings headwinds Jefferies cut Cigna to Hold and lowered its 2027 EPS estimate, citing uncertainty around the EviCore and HIX strategic reviews, reduced GLP-1 coverage, and PBM regulatory pressure. This weighs on the stock because it signals slower growth and limited near-term catalysts.
This is a new analyst action that directly lowers expectations for Cigna's future earnings, a key driver of the stock price.
Warren bill targets PBM vertical integration Senator Warren is pushing a bipartisan bill to break up vertically integrated healthcare companies, explicitly naming Cigna as one of the three major PBMs. If passed, it could force divestitures and reshape Cigna's business model, creating regulatory overhang that pressures the stock.
This is a new regulatory threat that could fundamentally alter Cigna's structure and profitability, directly impacting investor sentiment.
Employer survey shows high rebidding risk but PBM strength UBS survey shows 77% of employers will rebid health contracts for 2027, with Cigna among those with high exposure. However, Cigna's Express Scripts PBM is cited as likely to improve its market position, a positive offset. The net effect is uncertain but highlights competitive pressures.
This new survey data reveals both a risk (high rebidding) and an opportunity (PBM strength) that could affect Cigna's future revenue and market share.
AI expansion and new 'Lead to One' strategy Cigna is expanding AI care coordination and Pharmacy Forward, which could cut costs and improve outcomes. At its Investor Day, it reaffirmed 2026 guidance and set long-term targets of 10-14% EPS CAGR and $50B cumulative operating cash flow, plus a $3B modernization initiative. These support the stock by showing innovation and growth commitment.
These new initiatives and reaffirmed guidance provide a positive counterweight to the negative headwinds, showing management's confidence and potential for efficiency gains.

July 202621 Jun – 30 Jul 2026

▲3▼1

Cigna beats Q2, raises guidance as AI and Evernorth fuel growth

Q2 beat and raised guidance Cigna reported Q2 adjusted EPS of $7.78, beating the $7.59 consensus, and revenue of $71.7 billion, up 7% and above estimates. Management raised full-year 2026 adjusted EPS guidance to at least $30.45, up a dime. This directly boosts investor confidence and supports a higher stock price.
This is the most recent and concrete positive catalyst, showing the company is performing better than expected and raising its outlook.
Evernorth's AI-powered Pharmacy Forward launch Evernorth launched Pharmacy Forward, a $100 million AI program to speed specialty drug access, aiming to halve delivery time and generate about $400 million in value by 2028. This expands Cigna's health services beyond insurance, potentially driving future revenue and efficiency gains.
It is a new strategic initiative that could improve margins and growth in Cigna's largest segment, Evernorth.
Cigna Healthcare expands AI care management Cigna Healthcare is expanding AI-enabled care management to reach 20% more customers, expecting $200 million in savings over three years and reducing medical costs by $2,000 per engaged customer. This should lower costs and improve outcomes, supporting profitability.
It shows tangible cost savings and efficiency improvements from AI, which can boost earnings and justify a higher valuation.
UBS warns AI gains may be competed away UBS analysts said hospitals may benefit more durably from AI than insurers, because insurers' AI efficiency gains are easily copied and could be competed away through pricing. This creates a risk that Cigna's AI investments won't lead to lasting margin expansion.
It provides a counterweight to the positive AI news, highlighting a competitive threat that could limit long-term upside.

21 Jun – 30 Jul 2026

▲3▼1

Cigna beats Q2, raises guidance as AI and Evernorth fuel growth

Q2 beat and raised guidance Cigna reported Q2 adjusted EPS of $7.78, beating the $7.59 consensus, and revenue of $71.7 billion, up 7% and above estimates. Management raised full-year 2026 adjusted EPS guidance to at least $30.45, up a dime. This directly boosts investor confidence and supports a higher stock price.
This is the most recent and concrete positive catalyst, showing the company is performing better than expected and raising its outlook.
Evernorth's AI-powered Pharmacy Forward launch Evernorth launched Pharmacy Forward, a $100 million AI program to speed specialty drug access, aiming to halve delivery time and generate about $400 million in value by 2028. This expands Cigna's health services beyond insurance, potentially driving future revenue and efficiency gains.
It is a new strategic initiative that could improve margins and growth in Cigna's largest segment, Evernorth.
Cigna Healthcare expands AI care management Cigna Healthcare is expanding AI-enabled care management to reach 20% more customers, expecting $200 million in savings over three years and reducing medical costs by $2,000 per engaged customer. This should lower costs and improve outcomes, supporting profitability.
It shows tangible cost savings and efficiency improvements from AI, which can boost earnings and justify a higher valuation.
UBS warns AI gains may be competed away UBS analysts said hospitals may benefit more durably from AI than insurers, because insurers' AI efficiency gains are easily copied and could be competed away through pricing. This creates a risk that Cigna's AI investments won't lead to lasting margin expansion.
It provides a counterweight to the positive AI news, highlighting a competitive threat that could limit long-term upside.

Laboratory Corporation of America Holdings (LH)

Q3 202622 Jun – 22 Sep 2026

▲2▼1

Labcorp launches new tests, raises guidance, but Medicare fee cut proposal weighs

New product launches and Medicare coverage Labcorp launched ColoSense, the first FDA-approved at-home RNA colorectal cancer test, gained Medicare coverage for NASHnext, and introduced the first FDA-cleared Alzheimer's blood test. These expand its testing menu and open new revenue streams.
These launches are new in Q3 and show innovation driving growth.
Strong financial performance and raised guidance Labcorp beat Q2 estimates, raised its 2026 guidance, completed a large buyback, and set long-term revenue growth targets of 5%–8%. This signals confidence in its business and returns cash to shareholders.
These are new financial updates that positively influenced investor sentiment.
Proposed Medicare lab fee cuts CMS proposed cutting Medicare lab fees by up to 15% starting January 2027, citing overpayment versus private insurers. This sharply pressured Labcorp and Quest shares, raising concerns about future margins and revenue.
This is a new regulatory threat that negatively impacted the stock.
Reaffirmed outlook despite reimbursement pressure Labcorp reaffirmed its 2026–2029 outlook, saying it already assumed reimbursement pressure. However, the stock still fell about 3% in Q3, reflecting investor caution over potential margin and revenue risks.
This shows the counterweight: management confidence versus market skepticism.

September 202628 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

Latest28 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

July 202622 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.

22 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.